Halozyme's Royalty Highway: A Mid-Term Swing Trade to Ride the Delivery Monetization
Halozyme has quietly converted its enzyme platform into a high-margin royalty engine and is layering in M&A to accelerate growth. With 2026 guidance calling for >$1B in royalty revenue and adjusted EBITDA near $1.1B, the stock at ~$66 offers a tactical swing entry to capture a re-rating tied to continued partner sales and integration of Surf Bio. T…